 | In a letter to the Institute for Clinical and Economic Review (ICER), PIPC submitted comments on ICER's assessment of Iptacopan and Danicopan for Paroxysmal Nocturnal Hemoglobinuria (PNH). |
The letter criticizes ICER's choice of model for underestimating the complexity of PNH and ignoring major aspects of disease burden. PIPC also encourages ICER to rely more heavily on real world evidence, as well as make more of an effort to address patient heterogeneity.
"PIPC urges ICER to consider models that do not rely on quality-adjusted life years or equal value of life year gained measures in its studies," wrote PIPC Chair Tony Coelho. "A model that allows for consideration of the complexity of a disease, the impact of treatment for different subpopulations, and the broader set of costs and savings for patients, medical and non-medical, would allow for a more accurate value assessment."
"PIPC urges ICER to consider models that do not rely on quality-adjusted life years or equal value of life year gained measures in its studies," wrote PIPC Chair Tony Coelho. "A model that allows for consideration of the complexity of a disease, the impact of treatment for different subpopulations, and the broader set of costs and savings for patients, medical and non-medical, would allow for a more accurate value assessment."
| pipc_icer_pnh_final.pdf |
